These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

592 related items for PubMed ID: 27856088

  • 41. Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Lee J, Hoke ME, Estilo A, Sergeyeva O.
    Clin J Am Soc Nephrol; 2020 Dec 31; 16(1):48-58. PubMed ID: 33376102
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. An update on tolvaptan for autosomal dominant polycystic kidney disease.
    Poch E, Rodas L, Blasco M, Molina A, Quintana L.
    Drugs Today (Barc); 2018 Sep 31; 54(9):519-533. PubMed ID: 30303493
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Tolvaptan in Japanese patients with later-stage autosomal dominant polycystic kidney disease.
    Oguro M, Kogure Y, Hoshino J, Ubara Y, Mizuno H, Sekine A, Kawada M, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Sawa N, Takaichi K.
    J Nephrol; 2018 Dec 31; 31(6):961-966. PubMed ID: 30357715
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD: A Randomized Crossover Trial.
    Kramers BJ, Koorevaar IW, van Gastel MDA, van Goor H, Hallows KR, Heerspink HL, Li H, Leonhard WN, Peters DJM, Qiu J, Touw DJ, Gansevoort RT, Meijer E.
    Clin J Am Soc Nephrol; 2022 Apr 31; 17(4):507-517. PubMed ID: 35314480
    [Abstract] [Full Text] [Related]

  • 50. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
    Janssens P, Weydert C, De Rechter S, Wissing KM, Liebau MC, Mekahli D.
    Pediatr Nephrol; 2018 Mar 31; 33(3):395-408. PubMed ID: 28455745
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.
    Blair HA.
    Drugs; 2019 Feb 31; 79(3):303-313. PubMed ID: 30689194
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. [Treatment of autosomal dominant polycystic kidney disease (ADPKD) - Tolvaptan].
    Cirillo M.
    G Ital Nefrol; 2016 Feb 31; 33(5):. PubMed ID: 27796022
    [Abstract] [Full Text] [Related]

  • 56. Pro: Tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
    Torres VE.
    Nephrol Dial Transplant; 2019 Jan 01; 34(1):30-34. PubMed ID: 30312438
    [Abstract] [Full Text] [Related]

  • 57. Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD).
    Makabe S, Mochizuki T, Mitobe M, Aoyama Y, Kataoka H, Tsuchiya K, Nitta K.
    Clin Exp Nephrol; 2018 Oct 01; 22(5):1079-1087. PubMed ID: 29508162
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.